Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02348 DAWNRAYS PHARMA
RTNominal down1.170 -0.020 (-1.681%)
Others

16/07/2019 14:49

Dawnrays Pharma (02348) drug gets consistency approval

[ET Net News Agency, 16 July 2019] Dawnrays Pharmaceutical (Holdings) Limited (02348)
said "Levocetirizine Dihydrochloride Tablets 5mg", an anti-allergic drug of Suzhou
Dawnrays Pharmaceutical Co., Ltd., a subsidiary of the group (Suzhou Dawnrays), has been
granted approval by National Medical Products Administration for passing the consistency
of quality and efficacy evaluation of generic drugs.
Meanwhile, an anti-infective drug of Suzhou Dawnrays, "Cefoperazone Sodium and
Tazobactam Sodium for Injection (4:1) 1.0g and 2.0g", has obtained approval for drug
registration by the National Medical Products Administration.
With the effect of selective histamine H1 receptor antagonist, Levocetirizine
Dihydrochloride is an anti-allergic drug commonly used clinically for curing
allergy-related syndromes of diseases such as seasonal allergic rhinitis, perennial
allergic rhinitis and chronic idiopathic urticaria.
Cefoperazone Sodium and Tazobactam Sodium for Injection (4:1) is a an anti-infective
compound combination of Cefoperazone Sodium, the third generation of the cephalosporins,
and Tazobactam Sodium. (RC)

Remark: Real time quote last updated: 24/04/2024 17:46
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.